BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

April 5 (Reuters) - Antares Pharma Inc:

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

* FDA CONSIDERED RESUBMISSION A COMPLETE, CLASS 2 RESPONSE & HAS ASSIGNED USER FEE GOAL DATE OF SEPT. 29, 2018 Source text for Eikon: Further company coverage: